News headlines about Neovasc (NASDAQ:NVCN) have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neovasc earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 47.3567531536007 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern’s scoring:
- Stock Performance Check on Shares of Neovasc Inc. (NASDAQ … - Jonesboro Recorder (jonesbororecorder.com)
- Neovasc, Inc. :NVCN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 (finance.yahoo.com)
- Active Runners in Focus: Neovasc Inc (NVCN) and Genetic Technologies Ltd (GENE) - Evergreen Caller (evergreencaller.com)
- Should Farsighted Investors Pay Attention to Neovasc Inc. (NASDAQ:NVCN)? - FLBC News (flbcnews.com)
- Active Runner in Focus – Neovasc Inc (NVCN.TO) - Evergreen Caller (evergreencaller.com)
Separately, Zacks Investment Research downgraded Neovasc from a “hold” rating to a “sell” rating in a research note on Wednesday, August 16th.
Shares of Neovasc (NVCN) traded down 4.8333% during trading on Friday, reaching $0.7994. 134,377 shares of the company traded hands. The firm’s 50 day moving average is $1.12 and its 200-day moving average is $1.41. The stock’s market capitalization is $63.08 million. Neovasc has a 12-month low of $0.45 and a 12-month high of $3.34.
Neovasc (NASDAQ:NVCN) last issued its quarterly earnings data on Thursday, August 10th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by $0.02. Neovasc had a negative return on equity of 58.08% and a negative net margin of 68.34%. The firm had revenue of $1.31 million during the quarter, compared to analysts’ expectations of $1.40 million. On average, equities research analysts anticipate that Neovasc will post ($0.31) earnings per share for the current fiscal year.
Neovasc Company Profile
Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.
Receive News & Ratings for Neovasc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
